概览
Short Courses: October 29
Meeting: October 30-31
The DIA Annual Canadian Meeting will deliver a comprehensive overview of the current bio-pharma and device landscape in Canada, while sharing insights into Canada’s broader role in global healthcare product development. From policy updates and priorities shared directly from Health Canada, to sessions on international work sharing and partnerships to key regulatory and clinical considerations for drugs and devices, you will have the exclusive opportunity to address the current issues and opportunities in Canada and across the globe.
Bringing together key stakeholders from the drug (innovator and generic/biosimilar)/, device and Patient Self Care industries, regulatory agencies, and academia, this meeting will discuss/analyze the relevant challenges and opportunities for professionals working in the field in Canada.
This year’s meeting will feature preconference short courses, plenary sessions, multi-track breakout sessions and multiple networking opportunities.
项目委员会
-
Karen Feltmate President
Redstone Health Group, Inc., Canada -
Marc Poitras, PhD, MBA Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
Health Canada, Canada -
Marilena Bassi, MA Senior Executive Director, Therapeutic Products Directorate
Health Canada, Canada -
Lisa Chartrand Director, Regulatory Strategy and Policy
Hoffmann-La Roche Limited, Canada -
Loretta Del Bosco Director, Regulatory Affairs Quality Assurance Operations
AbbVie Corporation, Canada -
Fiona M Frappier, PhD Senior Policy Analyst
Health Canada, Canada -
Lorella Garofalo, PhD Head of Regulatory Sciences
Pfizer Canada, Canada -
Melissa Hunt, MSc Director
Health Canada, Canada -
Rania Mouchantaf, PhD A/Executive Director, Marketed Pharmaceuticals Bureau, MHPD
Health Canada, Canada -
Lissa Murseli Manager
Health Canada, Canada -
Polina Ostrovsky, MPH Policy Analyst
Health Canada, Canada -
Kristin Willemsen, MS Vice President, Scientific & Regulatory Affairs
Food, Health & Consumer Products of Canada, Canada
